Thyrotropin-secreting pituitary adenoma responsive to bromocriptine therapy

Area of Science:

• Endocrinology
• Neuro-oncology
• Pituitary Disorders

Background:

• Thyrotropin-secreting pituitary adenomas are rare tumors.
• Diagnosis can be challenging, often following treatment for presumed Graves' disease.
• Elevated thyrotropin (TSH) levels persist despite thyroid hormone replacement.

Purpose of the Study:

• To report a case of a TSH-secreting pituitary adenoma.
• To evaluate the efficacy of bromocriptine in managing this condition.
• To demonstrate hormonal and structural response to dopamine agonist therapy.

Main Methods:

• Case presentation of a 32-year-old woman with a TSH-secreting pituitary adenoma.
• Hormonal assessment including thyrotropin levels.
• Magnetic resonance imaging (MRI) for tumor evaluation.
• Treatment with bromocriptine, initiated at 15 mg/day and increased to 30 mg/day.

Main Results:

• Bromocriptine therapy led to suppressed thyrotropin levels.
• Repeated MRI scans revealed significant shrinkage of the pituitary adenoma.
• The tumor did not threaten vital structures, supporting medical management.

Conclusions:

• TSH-secreting pituitary adenomas can respond to bromocriptine.
• High-dose dopamine agonist therapy is a viable treatment option.
• Consider bromocriptine before more invasive treatments for TSH-secreting adenomas.